Skip to main content
. Author manuscript; available in PMC: 2013 Mar 27.
Published in final edited form as: Breast Cancer Res Treat. 2011 Sep 14;133(2):437–445. doi: 10.1007/s10549-011-1763-0

Fig. 5.

Fig. 5

Effect of ex vivo treatment of BrCSC enriched cells on tumorgenicity in NOD/SCID mice. 2LMP cells were sorted using flow cytometry for CD44+/CD24−/ALDH+ BrCSC markers and the cells were allowed to recover for 13 h. Cells were treated with TRA-8, 2E12, adriamycin or IgG control for 3 h and implanted into the MFP of groups of five NOD/SCID mice. a Graph represents the average tumor size and number of tumors formed. Only 2/5 small, slow growing tumors were observed to develop within 50 days with TRA-8 treated cells while 5/5 tumors developed in the IgG, 2E12, and adriamycin treatment groups (P value <0.0001). b These are images taken of one representative mouse in each group at day 30 after implantation (dotted circle shows the tumor)